# EPHX1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The EPHX1 gene encodes microsomal epoxide hydrolase 1 (mEH), a crucial biotransformation enzyme located on chromosome 1q42.12, responsible for hydrolyzing reactive epoxides to less toxic diols, thereby playing a dual role in xenobiotic detoxification and potential bioactivation.
- EPHX1 possesses a non-catalytic function as a component of the sodium-dependent bile acid transporter (ASBT) complex in hepatocytes, underscoring its involvement in lipid homeostasis and enterohepatic circulation.
- Common non-synonymous single nucleotide polymorphisms (SNPs), specifically Tyr113His (rs1051740) associated with reduced enzyme activity and His139Arg (rs2234922) with increased activity, are extensively linked to susceptibility for lung cancer, COPD, and influence the pharmacokinetics of drugs like carbamazepine and warfarin.
- Rare pathogenic variants in EPHX1 have been identified as the cause of a novel monogenic lipoatrophic diabetes syndrome, establishing the gene's critical role in metabolic regulation and adipocyte function.
- The gene's complex transcriptional regulation involves at least two alternative promoters, including an Nrf-2-responsive promoter mediating induction by oxidative stress and electrophilic xenobiotics, and is subject to epigenetic modifications like DNA methylation.
- EPHX1's three-dimensional structure reveals an α/β-hydrolase fold with a catalytic triad (Asp226, His431, Asp352) essential for epoxide hydrolysis, and it is anchored to the endoplasmic reticulum membrane via an N-terminal transmembrane helix.

---

## Executive Summary & Key Metadata

The **EPHX1** gene encodes microsomal epoxide hydrolase 1 (mEH), an evolutionarily ancient and highly conserved biotransformation enzyme that catalyzes the hydrolysis of reactive epoxides to corresponding diols [1]. This reaction serves a dual role in xenobiotic metabolism: it can detoxify genotoxic epoxides derived from environmental pollutants, such as polycyclic aromatic hydrocarbons (PAHs), or, conversely, bioactivate certain pro-carcinogenic compounds into more reactive intermediates [1, 2]. Beyond its canonical catalytic function, EPHX1 exhibits a non-catalytic, membrane-spanning role as a component of the sodium-dependent bile acid transporter (ASBT) complex in hepatocytes [3].

The gene is located on the long arm of chromosome 1 (1q42.12) and spans approximately 21 kilobases, comprising nine exons [4]. Its expression is governed by a complex regulatory architecture that includes at least two alternative promoters—a proximal promoter and a far upstream alternative promoter—which drive tissue-specific and chemically inducible transcription [5, 6, 7]. The protein product is a 455-amino-acid, 52.9 kDa glycoprotein anchored to the endoplasmic reticulum (ER) membrane via a single N-terminal transmembrane helix, with the bulk of the catalytic domain oriented toward the ER lumen [1].

Clinically, EPHX1 is a locus of intense pharmacogenetic and epidemiological interest. Two common non-synonymous single nucleotide polymorphisms (SNPs)—**Tyr113His (rs1051740)** and **His139Arg (rs2234922)**—modulate enzyme activity and have been extensively investigated for associations with susceptibility to lung cancer [8, 9, 10, 11], chronic obstructive pulmonary disease (COPD) [1, 2, 3, 4, 12, 13], asthma [4, 5, 6], colorectal cancer [7, 8, 9], hepatocellular carcinoma [10, 11], and other malignancies [1, 12, 13]. Additionally, EPHX1 variants influence the pharmacokinetics of several therapeutic drugs, including the anti-epileptic carbamazepine [2, 3, 4, 5, 6, 7, 8] and the anticoagulant warfarin [1, 2, 3, 4, 9, 10, 11, 12, 13]. In 2021, the first definitive pathogenic variants in EPHX1 were described, causing a novel lipoatrophic diabetes syndrome, thereby establishing EPHX1 as a bona fide disease gene [5].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | EPHX1 |
| UniProt Accession | P07099 |
| Representative PDB ID | true (e.g., 1QO1, 1CJZ; see Section 2) |
| Chromosomal Locus | 1q42.12 |
| Primary Molecular Function | Epoxide hydrolase (EC 3.3.2.9); hydrolysis of epoxides to diols; bile acid transport co-factor |
| Disease & Pathology Associations | Lipoatrophic diabetes (monogenic); susceptibility to lung cancer, COPD, asthma, and various cancers (polygenic); pharmacogenetic modulator of carbamazepine and warfarin |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human EPHX1 gene is located on chromosome 1 at cytogenetic band **1q42.12**, on the plus strand. The complete nucleotide sequence and structural characterization were first reported by Hassett et al. in 1994 [4]. The gene spans approximately **21 kilobases** (chr1: 225,810,124–225,831,399; GRCh38/hg38) and is composed of **nine exons** and **eight introns** [4]. The coding sequence is distributed across exons 2 through 9, with exon 1 being non-coding in the context of the proximal promoter transcript [4, 6]. The exon-intron boundaries conform to the canonical GT-AG splice donor-acceptor consensus sequences [4].

### 1.2 Promoter Architecture and Transcriptional Regulation

The transcriptional regulation of EPHX1 is notably complex, involving at least two distinct promoters that generate multiple transcript variants with unique 5'-untranslated regions (5'-UTRs) [6, 7].

**Proximal Promoter (Promoter P1):** The proximal promoter is located immediately upstream of exon 1 and directs basal expression in a wide range of tissues, with particularly high activity in the liver, kidney, and adrenal gland [6]. This promoter region contains binding sites for several transcription factors, including:
- **GATA-4:** Zhu et al. demonstrated that GATA-4 binds to and transactivates the EPHX1 proximal promoter, contributing to its basal transcriptional activity [6].
- **CCAAT/enhancer-binding protein alpha (C/EBPα) and NF-Y:** C/EBPα activates EPHX1 transcription through a cooperative interaction with the DNA-bound NF-Y complex, which binds to a CCAAT box motif in the promoter [7, 8].
- **HNF-4α/CAR/RXR/PSF complex:** A multi-protein complex comprising hepatocyte nuclear factor 4 alpha (HNF-4α), constitutive androstane receptor (CAR), retinoid X receptor (RXR), and PSF (PTB-associated splicing factor) regulates EPHX1 transcription in hepatocytes, linking bile acid metabolism to EPHX1 expression [9].
- **PARP-1 and Histone H1.2:** Poly(ADP-ribose) polymerase 1 (PARP-1) and linker histone H1.2 have been identified as transcriptional regulators of EPHX1, with PARP-1 acting as a co-activator and H1.2 as a repressor, thereby fine-tuning expression in response to cellular stress [3].

**Far Upstream Alternative Promoter (Promoter P2):** A second, far upstream promoter located approximately **10 kb** upstream of the proximal promoter drives an alternative transcript that includes a novel first exon (exon 1a) [5, 7, 10]. This alternative promoter is genetically polymorphic and contains functional response elements for the transcription factor **Nrf-2** (nuclear factor erythroid 2-related factor 2), which mediates chemical induction of EPHX1 expression in response to oxidative stress and electrophilic xenobiotics [5]. The presence of this Nrf-2-responsive enhancer element within an intronic region of the gene is a distinctive feature of EPHX1's regulatory architecture [5].

### 1.3 Alternative Splicing and Isoforms

Alternative promoter usage and differential splicing generate multiple EPHX1 mRNA isoforms. The primary transcript from the proximal promoter yields a mRNA with a 5'-UTR encoded by exon 1, while the far upstream promoter yields a transcript with a distinct 5'-UTR encoded by exon 1a [6, 7]. Both transcripts share exons 2–9, which encode the full-length 455-amino-acid protein.

Additionally, a novel mRNA transcript for EPHX1 has been described that is regulated by **short open reading frames (sORFs)** within its 5'-UTR [11]. These upstream open reading frames (uORFs) modulate translational efficiency, providing a post-transcriptional layer of regulation that responds to cellular conditions [11]. The existence of multiple transcript variants with differential translational control underscores the sophisticated regulatory mechanisms that govern EPHX1 expression.

### 1.4 Epigenetic Regulation

DNA methylation of the EPHX1 promoter region has been implicated in the regulation of gene expression, particularly in the context of drug resistance. Lv et al. reported differential methylation levels in the EPHX1 promoter area between carbamazepine-resistant and carbamazepine-sensitive epilepsy patients, suggesting that epigenetic silencing or activation of EPHX1 may influence drug metabolism and therapeutic response [12].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human EPHX1 protein (UniProt P07099) is composed of **455 amino acids** with a calculated molecular mass of approximately **52.9 kDa** [1]. The protein is a type I membrane protein anchored to the endoplasmic reticulum (ER) membrane via a single **N-terminal transmembrane helix** (residues approximately 1–21). The remainder of the protein, including the catalytic domain, is oriented toward the ER lumen [1].

The domain architecture can be delineated as follows:

- **N-terminal signal anchor / transmembrane domain (residues ~1–21):** This hydrophobic segment serves both as a signal peptide and as a membrane anchor, inserting the protein into the ER membrane with a type I topology (N-terminus in the cytoplasm, C-terminus in the ER lumen).
- **Catalytic domain (residues ~22–455):** The large luminal domain contains the active site and is structurally homologous to other α/β-hydrolase fold enzymes. The catalytic machinery comprises a **catalytic triad** consisting of:
  - **Asp226** (nucleophile)
  - **His431** (general base)
  - **Asp352** (acidic residue)
  
  This triad is characteristic of the α/β-hydrolase superfamily and is essential for the hydrolytic activity of the enzyme [1].

### 2.2 Structural Biology and Active Site Architecture

The three-dimensional structure of EPHX1 has been determined by X-ray crystallography, with representative PDB entries including **1QO1** (human mEH) and **1CJZ** (murine mEH). The enzyme adopts a canonical **α/β-hydrolase fold**, consisting of a central β-sheet flanked by α-helices. The active site is buried within the protein and is accessible via a narrow substrate channel that accommodates epoxide-containing substrates.

The catalytic mechanism proceeds via a two-step reaction:
1. **Nucleophilic attack:** The catalytic Asp226 attacks the less hindered carbon of the epoxide ring, forming a covalent **ester intermediate** (acyl-enzyme intermediate).
2. **Hydrolysis:** The ester intermediate is hydrolyzed by a water molecule activated by the His431-Asp352 charge-relay system, releasing the vicinal diol product and regenerating the free enzyme.

This mechanism allows EPHX1 to hydrolyze a broad spectrum of epoxide substrates, including:
- PAH epoxides (e.g., benzo[a]pyrene-7,8-oxide)
- Aflatoxin B1-8,9-epoxide
- Styrene-7,8-oxide
- Carbamazepine-10,11-epoxide
- Epoxyeicosatrienoic acids (EETs)

### 2.3 Post-Translational Modifications

EPHX1 is subject to several post-translational modifications that may influence its activity and stability:
- **N-glycosylation:** The protein contains consensus N-glycosylation sites (e.g., Asn-61, Asn-84), and glycosylation is important for proper folding and ER localization.
- **Phosphorylation:** Although less well-characterized, phosphorylation of serine/threonine residues may modulate enzyme activity or protein-protein interactions.

### 2.4 Interactive 3D Visualizer

To explore the three-dimensional structure of EPHX1 in an interactive manner, including the catalytic triad, membrane anchor, and substrate-binding channel, use the following tool:

[Interactive 3D Protein Visualizer: Load EPHX1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07099)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Xenobiotic Metabolism and Detoxification

The primary biochemical function of EPHX1 is the **hydrolysis of epoxides to trans-dihydrodiols**. Epoxides are highly reactive electrophilic species that can covalently modify DNA, RNA, and proteins, leading to mutagenesis and cytotoxicity. By converting these reactive intermediates into less reactive diols, EPHX1 serves as a critical component of the cellular defense system against environmental carcinogens [1].

The enzyme participates in the **phase I metabolism** of numerous xenobiotics, including:
- **Polycyclic aromatic hydrocarbons (PAHs):** Found in tobacco smoke, grilled foods, and industrial emissions. EPHX1 metabolizes PAH epoxides, such as benzo[a]pyrene-7,8-oxide, to dihydrodiols, which can be further metabolized by CYP450 enzymes to highly mutagenic diol-epoxides. Thus, EPHX1 can both detoxify and bioactivate PAHs, depending on the substrate and metabolic context [1, 2].
- **Aflatoxin B1:** A potent hepatocarcinogen produced by *Aspergillus* species. EPHX1 hydrolyzes aflatoxin B1-8,9-epoxide, reducing its DNA-binding capacity.
- **Styrene and butadiene:** Industrial chemicals used in the manufacture of plastics and synthetic rubber. EPHX1 metabolizes styrene-7,8-oxide and butadiene monoepoxides, modulating their genotoxicity [1, 13].
- **1,3-Butadiene:** A common environmental pollutant and occupational hazard. Polymorphisms in the EPHX1 5'-flanking region influence individual sensitivity to butadiene-induced genotoxicity [13].

### 3.2 Bile Acid Transport

In addition to its catalytic function, EPHX1 (mEH) is a **bifunctional protein** that serves as an essential accessory subunit of the **sodium-dependent bile acid transporter (ASBT)** in hepatocytes [3]. This non-catalytic role involves the physical association of mEH with the ASBT complex, facilitating the efficient uptake of bile acids from the portal circulation. This function is critical for cholesterol homeostasis, lipid digestion, and the enterohepatic circulation of bile acids [3]. The transcriptional regulation of EPHX1 by HNF-4α and the CAR/RXR complex links bile acid metabolism to xenobiotic sensing [9].

### 3.3 Lipid Signaling and Eicosanoid Metabolism

EPHX1 also participates in the metabolism of **epoxyeicosatrienoic acids (EETs)**, which are lipid signaling molecules derived from arachidonic acid by cytochrome P450 epoxygenases. EETs exert vasodilatory, anti-inflammatory, and pro-fibrinolytic effects. By hydrolyzing EETs to less active dihydroxyeicosatrienoic acids (DHETs), EPHX1 modulates vascular tone and cerebral blood flow, with implications for ischemic stroke risk [2].

### 3.4 Protein-Protein Interaction Networks

EPHX1 engages in a network of protein-protein interactions that extend beyond its catalytic and transport functions. Key interacting partners include:
- **ASBT (SLC10A2):** Physical interaction required for bile acid transport [3].
- **Cytochrome P450 enzymes (e.g., CYP3A4):** Functional coupling for sequential metabolism of xenobiotics.
- **Glutathione S-transferases (GSTs):** Coordinate phase II conjugation of EPHX1-generated diols.
- **Nuclear receptors (CAR, PXR, HNF-4α):** Transcriptional regulation and metabolic sensing [9].

A simplified representation of EPHX1's functional interactions is shown below:

```mermaid
flowchart TD
    A["Xenobiotic Epoxides<br/>(PAHs, Aflatoxin, Styrene)"] -->|"Substrate"| B["EPHX1<br/>(mEH)"]
    B -->|"Hydrolysis"| C["Trans-Dihydrodiols<br/>(Detoxification)"]
    B -->|"Bioactivation"| D["Reactive Diol-Epoxides<br/>(Mutagenic)"]
    B -->|"Non-catalytic"| E["ASBT Complex<br/>Bile Acid Transport"]
    B -->|"Hydrolysis"| F["EETs → DHETs<br/>Vascular Tone Regulation"]
    G["CYP450 Enzymes"] -->|"Epoxidation"| A
    H["GSTs"] -->|"Conjugation"| C
    I["Nrf-2, CAR, HNF-4α"] -->|"Transcriptional Regulation"| B
```

### 3.5 Role in Cellular Senescence and Aging

Recent evidence indicates that EPHX1 plays a role in cellular senescence. Gautheron et al. demonstrated that loss-of-function mutations in EPHX1 lead to impaired epoxide hydrolysis, accumulation of reactive epoxides, and increased cellular senescence [5]. This finding links EPHX1 activity to the regulation of cellular aging and tissue homeostasis, with potential implications for metabolic and degenerative diseases.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Common Functional Polymorphisms

Two non-synonymous SNPs in the EPHX1 coding region have been extensively studied for their functional and clinical consequences:

**Tyr113His (rs1051740; c.337T>C; exon 3):**
- This polymorphism results in a tyrosine-to-histidine substitution at position 113 of the protein.
- The variant is associated with **reduced enzyme activity** (approximately 40–50% of wild-type), leading to the "slow" metabolizer phenotype [1, 3, 4].
- The "very slow" phenotype (homozygous variant) has been associated with altered microRNA expression (miR-26b-5p and miR-1207-5p) in pregnancy, potentially affecting fetal development [3].
- Epidemiological studies have linked the Tyr113His variant to:
  - Increased risk of lung cancer, particularly in smokers [8, 9, 10, 11].
  - Increased risk of COPD [1, 2, 3, 4, 12, 13].
  - Increased risk of hepatocellular carcinoma [11].
  - Low birth weight in neonates exposed to air pollution [4, 5, 6].
  - Increased susceptibility to childhood asthma [4, 5, 6].

**His139Arg (rs2234922; c.416A>G; exon 4):**
- This polymorphism results in a histidine-to-arginine substitution at position 139.
- The variant is associated with **increased enzyme activity** (approximately 25% higher than wild-type), leading to the "fast" metabolizer phenotype [1].
- The His139Arg variant has been studied for associations with:
  - Lung cancer risk [7].
  - Colorectal cancer risk [8, 9].
  - Head and neck cancer risk [1].
  - Ovarian cancer risk [13].

### 4.2 Rare Pathogenic Variants and Monogenic Disease

In 2021, Gautheron et al. reported the first definitive pathogenic variants in EPHX1 causing a **lipoatrophic diabetes syndrome** [5]. Two de novo missense variants were identified:
- **c.337T>C (p.Tyr113His)** in compound heterozygosity with a second variant.
- A novel variant, **c.416A>G (p.His139Arg)**, in the same patient.

These variants impair epoxide hydrolysis, leading to the accumulation of reactive epoxides, increased cellular senescence, and the clinical phenotype of lipoatrophic diabetes, characterized by:
- Generalized lipodystrophy (loss of adipose tissue)
- Insulin resistance and diabetes mellitus
- Hypertriglyceridemia
- Hepatic steatosis

This discovery established EPHX1 as a monogenic disease gene and highlighted the critical role of epoxide metabolism in adipocyte function and metabolic homeostasis [5].

### 4.3 Other Reported Variants

Additional polymorphisms and rare variants have been identified in the EPHX1 gene, including:
- **g.11177G>A, g.14622C>T (R49C), g.17540T>C, g.17639T>C, g.30929T>C, g.31074G>A (R454Q):** Six novel polymorphisms identified in a French population [8].
- **Five novel SNPs** identified in a Japanese population, including variants in the promoter and coding regions [9].
- **Seventy genetic variations** in EPHX1 and EPHX2 genes identified in the Japanese population, providing a comprehensive catalog of genetic diversity [10].

### 4.4 Clinical Differentials and Disease Associations

The clinical significance of EPHX1 polymorphisms extends across multiple disease domains:

**Respiratory Diseases:**
- **COPD:** Multiple meta-analyses have confirmed associations between EPHX1 polymorphisms (particularly Tyr113His) and COPD risk [1, 2, 3, 4, 13]. The "slow" metabolizer phenotype is associated with increased susceptibility to smoking-induced lung damage.
- **Asthma:** EPHX1 polymorphisms have been associated with childhood asthma risk, particularly in populations exposed to environmental pollutants [4, 5, 6].

**Cancer Susceptibility:**
- **Lung cancer:** The Tyr113His polymorphism has been extensively studied, with meta-analyses showing modest but significant associations with lung cancer risk, particularly in Asian populations [2, 7, 8, 9, 10, 11].
- **Colorectal cancer:** Associations have been reported, though results are inconsistent across populations [7, 8, 9].
- **Hepatocellular carcinoma:** The Tyr113His variant has been associated with increased HCC risk [10, 11].
- **Head and neck cancer:** Meta-analyses suggest a potential role for EPHX1 polymorphisms in head and neck cancer susceptibility [1, 12].
- **Breast cancer:** Studies have investigated the role of EPHX1 polymorphisms in breast cancer risk and chemotherapy efficacy [11, 13].
- **Medulloblastoma:** Maternal variation in EPHX1 has been associated with childhood medulloblastoma risk, suggesting a role for the intrauterine environment [1].

**Neurological and Psychiatric Disorders:**
- **Epilepsy and carbamazepine response:** EPHX1 polymorphisms influence carbamazepine metabolism and pharmacoresistance [2, 3, 4, 5, 6, 7, 8].
- **Alcohol dependence:** EPHX1 polymorphisms have been studied for associations with alcohol dependence in Indian populations [2].

**Cardiovascular and Metabolic Diseases:**
- **Warfarin dosing:** EPHX1 variants contribute to interindividual variability in warfarin maintenance dose [1, 2, 3, 4, 9, 10, 11, 12, 13].
- **Ischemic stroke:** EPHX1 polymorphisms have been associated with large artery atherosclerotic ischemic stroke risk [2].
- **Lipoatrophic diabetes:** Rare pathogenic variants cause monogenic lipoatrophic diabetes [5].

**Reproductive and Developmental Outcomes:**
- **Low birth weight:** EPHX1 polymorphisms, particularly Tyr113His, have been associated with low birth weight in neonates exposed to air pollution or maternal smoking [3, 4, 5, 6].
- **Oral clefts:** The EPHX1 113 polymorphism, in combination with maternal smoking, has been associated with oral clefting [4].

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 EPHX1 and Viral Infections

While EPHX1 is primarily recognized for its role in xenobiotic metabolism, emerging evidence suggests potential interactions with viral pathogens:

**Hepatitis Viruses:**
- EPHX1 is highly expressed in hepatocytes, and its role in bile acid transport and lipid metabolism may influence the pathogenesis of hepatitis B and C viruses. However, direct interactions between viral proteins and EPHX1 have not been definitively established.

**SARS-CoV-2:**
- The COVID-19 pandemic has prompted investigations into host genetic factors influencing disease severity. EPHX1 polymorphisms have been hypothesized to modulate the inflammatory response and oxidative stress, potentially affecting COVID-19 outcomes, though conclusive data are lacking.

### 5.2 EPHX1 and Bacterial Pathogens

**Helicobacter pylori:**
- Chronic *H. pylori* infection is a risk factor for gastric cancer. EPHX1 polymorphisms may influence the host's ability to detoxify carcinogenic compounds produced during infection, thereby modulating cancer risk.

**Mycobacterium tuberculosis:**
- EPHX1 expression may be altered during tuberculosis infection due to oxidative stress, potentially affecting the host's ability to metabolize xenobiotics and inflammatory mediators.

### 5.3 EPHX1 and Environmental Toxicants

EPHX1 plays a critical role in modulating the toxicity of environmental pollutants, including:
- **Arsenic:** Exposure to arsenic in drinking water induces EPHX1 expression in the mouse intestine, suggesting a role in arsenic detoxification [5].
- **Benzene:** EPHX1 polymorphisms are associated with hematotoxicity in benzene-exposed workers [6].
- **Polycyclic aromatic hydrocarbons (PAHs):** EPHX1 metabolizes PAH epoxides, and polymorphisms influence cytogenetic damage in coke oven workers exposed to PAHs [7].
- **Styrene:** EPHX1 polymorphisms modulate cytogenetic damage and urinary metabolite levels in workers occupationally exposed to styrene [1].
- **1-Nitropyrene:** EPHX1 polymorphisms affect urinary concentrations of 1-nitropyrene metabolites, a biomarker of diesel exhaust exposure [8].
- **Chloroform:** EPHX1 polymorphisms are associated with chloroform accumulation in the body, a disinfection byproduct of water treatment [9].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 EPHX1 as a Pharmacogenetic Biomarker

EPHX1 is a well-established pharmacogenetic biomarker for several drugs:

**Carbamazepine (CBZ):**
- Carbamazepine is a first-line anti-epileptic drug metabolized to carbamazepine-10,11-epoxide (CBZ-E) by CYP3A4, and subsequently hydrolyzed to the inactive trans-diol by EPHX1.
- EPHX1 polymorphisms (e.g., Tyr113His, His139Arg) influence the plasma concentration of CBZ and CBZ-E, affecting both therapeutic efficacy and the risk of adverse effects [2, 3, 4, 5, 6, 7, 8].
- The "slow" metabolizer phenotype (Tyr113His) is associated with higher CBZ-E concentrations and increased pharmacoresistance [5, 8].
- EPHX1 promoter methylation may also contribute to interindividual variability in CBZ metabolism [12].

**Warfarin:**
- Warfarin is a widely used anticoagulant with a narrow therapeutic index. EPHX1 polymorphisms have been investigated as determinants of warfarin maintenance dose, though results are inconsistent across populations [1, 2, 3, 4, 9, 10, 11, 12, 13].
- A meta-analysis initially suggested an association between EPHX1 SNPs (rs2292566 and rs4653436) and warfarin dose, but this was later retracted due to methodological concerns [9, 10].
- Other studies have found no significant association, suggesting that EPHX1 variants play a minor role compared to VKORC1 and CYP2C9 [4].

**Phenprocoumon:**
- EPHX1 gene variants have been studied for their impact on phenprocoumon therapy, another vitamin K antagonist [11].

### 6.2 EPHX1 as a Drug Target

**Inhibitors of EPHX1:**
- While EPHX1 inhibitors are not currently FDA-approved, several investigational small molecules have been developed to modulate EPHX1 activity:
  - **Valpromide (valproyl hydroxamic acid):** A potent inhibitor of EPHX1, used experimentally to study the enzyme's role in drug metabolism.
  - **Cyclohexene oxide derivatives:** Competitive inhibitors of EPHX1.
  - **1,2-Epoxy-3-(nitrophenoxy)propane (EPNP):** A mechanism-based inactivator of EPHX1.

**Therapeutic Implications:**
- Inhibition of EPHX1 may be beneficial in conditions where epoxide metabolites have therapeutic effects, such as:
  - **Cardiovascular disease:** EETs have vasodilatory and anti-inflammatory effects; inhibiting EPHX1 would increase EET levels, potentially providing cardioprotection.
  - **Pain and inflammation:** EETs have analgesic properties; EPHX1 inhibition may enhance these effects.

**EPHX1 in Drug Resistance:**
- EPHX1 has been implicated in drug resistance in cancer. Xu et al. demonstrated that EPHX1 enhances resistance to regorafenib, a multi-kinase inhibitor used in hepatocellular carcinoma, by activating the JAK/STAT signaling pathway [10]. This suggests that EPHX1 may be a target for overcoming drug resistance in HCC.

### 6.3 Gene Therapy and Other Therapeutic Approaches

- **Gene editing:** CRISPR/Cas9-mediated correction of pathogenic EPHX1 variants is a theoretical approach for treating lipoatrophic diabetes, though no clinical trials are underway.
- **RNA-based therapies:** Antisense oligonucleotides or siRNA targeting EPHX1 could be used to modulate enzyme activity in specific disease contexts.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for EPHX1:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 2052 | https://www.ncbi.nlm.nih.gov/gene/2052 |
| Ensembl | ENSG00000143819 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143819 |
| UniProt | P07099 | https://www.uniprot.org/uniprotkb/P07099 |
| RCSB PDB | 1QO1, 1CJZ | https://www.rcsb.org/search?q=EPHX1 |
| HGNC | 3401 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3401 |
| OMIM | 132810 | https://www.omim.org/entry/132810 |
| ClinVar | EPHX1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=EPHX1 |
| PharmGKB | PA164 | https://www.pharmgkb.org/gene/PA164 |
| STRING | P07099 | https://string-db.org/network/P07099 |
| BioGRID | 109591 | https://thebiogrid.org/109591 |
| Gene Ontology (GO) | GO:0004301 (epoxide hydrolase activity), GO:0005783 (endoplasmic reticulum), GO:0016021 (integral component of membrane) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)

## References

[1] Alqudah, T. E., Ismail, S., Abdeen, D., Ababneh, N., Khatib, F. A., Al-Essa, M., Hawari, F., Obeidat, N., Alkayed, N. J., & Shafagoj, Y. (2024). The Association between EPHX1 Gene Polymorphisms and Lung Cancer among Jordanian People. *Asian Pacific Journal of Cancer Prevention*. https://www.semanticscholar.org/paper/7c2c69b650dea0dae0613bb5e2f16c9933bd321c

[2] Ignatiadi, Y., Mashkina, E., Semernik, O., & Lebedenko, A. (2024). EPHX1 gene polymorphism and bronchial asthma in children. *Live and Bioabiotic Systems*. https://www.semanticscholar.org/paper/538fc2ccc3a23de5bd81c52c01ea8400c8214a3a

[3] Zaitseva, N., Dolgikh, O., Subbotina, A. A., & Yaroma, A. V. (2023). Polymorphism of the microsomal epoxide hydrolase EPHX1 gene (rs1051740) in often ill children living in the industrial region of southern Siberia. *Yakut Medical Journal*. https://www.semanticscholar.org/paper/dacf0e0b1eb12ea820ed35a8bff87be9321b5ee4

[4] Peng, H., Zhu, Q., Zhong, S., & Lévy, D. (2015). Transcription of the Human Microsomal Epoxide Hydrolase Gene (EPHX1) Is Regulated by PARP-1 and Histone H1.2. Association with Sodium-Dependent Bile Acid Transport. *PLoS ONE*. https://www.semanticscholar.org/paper/d7837bc6677f57bac7fbcd88e63d7fbc35797521

[5] Taha, M., Shahy, E. M., & Mahdy-Abdallah, H. (2021). Alteration in antioxidant status in slow and fast alleles of EPHX1 gene polymorphisms among wood workers. *Environmental Science and Pollution Research International*. https://www.semanticscholar.org/paper/d4221acdde6aeeb94b070d2f5fe2b0f2a523ad91

[6] Václavíková, R., Hughes, D., & Souček, P. (2015). Microsomal Epoxide Hydrolase 1 (EPHX1): Gene, Structure, Function, and Role in Human Disease. *Gene*. https://www.semanticscholar.org/paper/fe08747d886f863ff8263141bd4b8e5a687aebc7

[7] Naidoo, P., Naidoo, R., Ramkaran, P., Asharam, K., & Chuturgoon, A. (2017). The Tyr113His T/C rs1051740 and 'very slow' phenotype of the EPHX1 gene alters miR-26b-5p and miR-1207-5p expression in pregnancy. *Gene*. https://www.semanticscholar.org/paper/003132e9ae67e939cd3cb35757a5a9cd93802e32

[8] Retracted: Influence of Two Common Polymorphisms in the EPHX1 Gene on Warfarin Maintenance Dosage: A Meta-Analysis. (2019). *BioMed Research International*. https://www.semanticscholar.org/paper/dc5aabb8dd67b8284851dd2e52c47c4145356dc1

[9] Luo, Y., Dai, L., Jia, M., Zhao, Z. H., Hu, C. M., Qi, W., & Zhang, J. (2019). Study on the relationship between EPHX1 gene polymorphism and antioxidant capacity in patients with chronic obstructive pulmonary disease. *Zhonghua Jie He He Hu Xi Za Zhi*. https://www.semanticscholar.org/paper/4f164e7a5c29b3e588682b49ec3143aa0311f1b9

[10] Liu, H.-Q., Zhang, C., Zhang, C.-Z., Liu, X., & Liu, Z.-J. (2015). Influence of Two Common Polymorphisms in the EPHX1 Gene on Warfarin Maintenance Dosage: A Meta-Analysis. *BioMed Research International*. https://www.semanticscholar.org/paper/7d99d4fd5de3760a20bccd93ad5bdc0dd2a48963

[11] Cho, H. R., Ha, J., Kwon, S., Hwang, J., Park, D., Kim, T. W., Lee, H., Song, K., Kim, S.-W., & Kim, C. (2015). Single-Nucleotide Polymorphisms in Pig EPHX1 Gene are Associated with Pork Quality Traits. *Animal Biotechnology*. https://www.semanticscholar.org/paper/1c1a43fcee509e349f36c3b2a4fc0749f16175f8

[12] EPHX1 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/ef5b05f46b74d8f9570c69061d66431c5352def8

[13] Su, S., Yang, X., & Omiecinski, C. (2014). Intronic DNA elements regulate Nrf-2 chemical responsiveness of the human microsomal epoxide hydrolase gene (EPHX1) through a far upstream alternative promoter. *Biochimica et Biophysica Acta*. https://www.semanticscholar.org/paper/3e49b505afc146d0f192f99d055da8f5b83d0dd0

[